Immunocompatible chorionic membrane products

Patent metadata

Field	Value
Publication number	US-12558377-B2
Application number	US-202217969461-A
Country	US
Kind code	B2
Filing date	Oct 19, 2022
Priority date	Feb 18, 2010
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

First claim

The invention claimed is:

1 . A method of treating a skin wound, the method comprising topically applying to the skin wound a placental product comprising a chorionic membrane,
wherein the chorionic membrane is substantially free of trophoblasts, and wherein the chorionic membrane comprises:
one or more matrix metalloproteases (MMPs) comprising MMP-9 and TIMP-1, wherein a ratio of MMP-9 to TIMP-1 is from about 7-10 to 1; and
viable cells native to the chorionic membrane,
wherein at least 70% of the cells native to the chorionic membrane are viable, and
wherein the viable cells comprise mesenchymal stem cells (MSCs) and fibroblasts wherein the placental product is cryopreserved, and wherein the method further comprises thawing the placental product prior to applying the placental product to the skin wound.

2 . The method of claim 1 , wherein the skin wound is selected from a chronic wound, an ulcer, a diabetic ulcer, a foot ulcer, a diabetic foot ulcer, a venous ulcer, a venous leg ulcer, a leg ulcer, a pressure ulcer, a burn, a thermal burn, a chemical burn, a partial thickness burn, or a full thickness burn.

3 . The method of claim 1 , wherein the skin wound is selected from a laceration, a scrape, an incision, a puncture, a wound caused by a projectile, an epidermal wound, a dermal wound, a surgical wound, an acute wound, a congenital wound, a toxic epidermal necrolysis, an epidermolysis bullosa, or a pyoderma gangrenosum.

4 . The method of claim 1 , wherein less than 5% of cells of the chorionic membrane are CD14+ macrophages.

5 . The method of claim 1 , wherein the chorionic membrane comprises one or more therapeutic factors native to the chorionic membrane.

6 . The method of claim 1 , wherein the chorionic membrane comprises extracellular matrix native to the chorionic membrane.

7 . The method of claim 1 , wherein the chorionic membrane is immunocompatible.

8 . The method of claim 1 , wherein the placental product further comprises a cryopreservation medium.

9 . The method of claim 1 , wherein the placental product further comprises an amniotic membrane wherein the amniotic membrane comprises a layer of amniotic epithelial cells.

Assignees

• Osiris Therapeutics Inc

Inventors

• Tom Samson
• Danilkovitch Alla
• Yoo Dana
• Jansen Timothy
• Kuang Jin-Qiang
• Marconi Jennifer Michelle

Classifications

• C12N2501/115

  Basic fibroblast growth factor (bFGF, FGF-2) · CPC title

• C12N5/0605

  Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly · CPC title

• A61K38/57

  from animals; from humans {(A61K38/553, A61K38/556 take precedence)} · CPC title

• A61K38/39

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title

• A61K38/1841

  Transforming growth factor [TGF] · CPC title